Back to top

Image: Bigstock

REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%

Read MoreHide Full Article

REGENXBIO Inc. (RGNX - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $42–$52.32 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

REGENXBIO currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Acorda Therapeutics, Inc. (ACOR - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is RGNX going up? Or down? Predict to see what others think:Up or Down

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Acorda Therapeutics, Inc. (ACOR) - free report >>

REGENXBIO Inc. (RGNX) - free report >>

Published in